Formycon AG/€FYB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Formycon AG
Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.
Ticker
€FYB
Sector
Primary listing
XETRA
Employees
245
Headquarters
Website
Formycon AG Metrics
BasicAdvanced
€403M
-
-€9.60
0.59
-
Price and volume
Market cap
€403M
Beta
0.59
52-week high
€64.40
52-week low
€19.18
Average daily volume
10K
Financial strength
Current ratio
1.541
Quick ratio
1.036
Long term debt to equity
2.121
Total debt to equity
2.499
Interest coverage (TTM)
-35.18%
Profitability
EBITDA (TTM)
113.228
Gross margin (TTM)
-0.99%
Net profit margin (TTM)
-327.88%
Operating margin (TTM)
-71.13%
Effective tax rate (TTM)
11.32%
Revenue per employee (TTM)
€210,000
Management effectiveness
Return on assets (TTM)
-2.72%
Return on equity (TTM)
-34.48%
Valuation
Price to revenue (TTM)
7.762
Price to book
0.99
Price to tangible book (TTM)
-8.42
Price to free cash flow (TTM)
-18.018
Free cash flow yield (TTM)
-5.55%
Free cash flow per share (TTM)
-1.261
Growth
Revenue change (TTM)
-14.84%
Earnings per share change (TTM)
-350.93%
3-year revenue growth (CAGR)
14.87%
10-year revenue growth (CAGR)
9.05%
3-year earnings per share growth (CAGR)
13.47%
Bulls say / Bears say
In Q1 2025, FYB203 (aflibercept biosimilar) received European Commission approval in January and UK approval in February 2025, with Teva Pharmaceuticals marketing in Europe and Lotus Pharmaceuticals covering Asia-Pacific, expanding Formycon’s geographic commercial footprint (Formycon).
Formycon exceeded its 2024 revenue guidance with group revenues of €69.7 million and delivered adjusted EBITDA of €–1.6 million, both outperforming forecasts, underscoring strong operational execution and financial resilience (Formycon).
The issuance of a €50 million unsecured corporate bond in June 2025 demonstrates investor confidence and strengthens the balance sheet to fund pipeline advancement, securing non-dilutive financing for growth (Formycon).
Formycon’s FYB201 (ranibizumab biosimilar) U.S. commercialization by Sandoz AG has been paused for approximately one year starting Q2 2025 due to competitive discounting, indicating challenges in penetrating the U.S. market and execution risk tied to a partner’s strategy (Formycon).
The group’s net working capital rose to €55.1 million at year-end 2024, above the previous forecast, reflecting significant capital tied up in pipeline development and balance sheet adjustments that could constrain liquidity (Formycon).
FYB202’s U.S. launch faces an unpredictable and highly competitive biosimilar market environment, making revenue recognition and penetration speed difficult to forecast, which adds volatility to near-term guidance (Formycon).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Formycon AG stock?
Formycon AG (FYB) has a market cap of €403M as of September 11, 2025.
What is the P/E ratio for Formycon AG stock?
The price to earnings (P/E) ratio for Formycon AG (FYB) stock is 0 as of September 11, 2025.
Does Formycon AG stock pay dividends?
No, Formycon AG (FYB) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next Formycon AG dividend payment date?
Formycon AG (FYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Formycon AG?
Formycon AG (FYB) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.